8-K - Atrium Therapeutics, Inc. (0002093101) (Filer)
Published . Updated .
Filed: 2026-10-08 AccNo: 0001193125-26-417402 Size: 685 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Directly affected
- RNA Atrium Therapeutics
Named in this report.
Indirectly affected
- SPY SPDR S&P 500
The broad U.S. stock market
- TLT iShares 20+ Year Treasury Bond
Long-term U.S. government bonds
- QQQ Invesco QQQ
Large technology stocks
- GLD SPDR Gold Shares
Gold can move with the broad market
Price reaction, T-5 to T+3
Filed: 2026-10-08 AccNo: 0001193125-26-417402 Size: 685 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Source: sec-edgar
Price since this story was published: Atrium Therapeutics (RNA)
Since the first closing price after “8-K - Atrium Therapeutics, Inc. (0002093101) (Filer),” Atrium Therapeutics (RNA) is -9.86%. The S&P 500 fund (SPY) is -1.53% over the same days, a -8.33% difference versus the market.
| Company | When | Move | Status |
|---|---|---|---|
| GLD | that day | +0.74% | final price |
| GLD | the next day | +2.33% | final price |
| GLD | two days later | +1.68% | final price |
| GLD | three days later | +1.54% | final price |
| GLD | three days earlier | +0.98% | final price |
| GLD | five days earlier | +1.84% | final price |
| QQQ | that day | -1.35% | final price |
| QQQ | the next day | -0.86% | final price |
| QQQ | two days later | -1.55% | final price |
| QQQ | three days later | -1.86% | final price |
| QQQ | three days earlier | -0.22% | final price |
| QQQ | five days earlier | -2.07% | final price |
| Atrium Therapeutics (RNA) | that day | +3.65% | final price |
| Atrium Therapeutics (RNA) | the next day | +5.72% | final price |
| Atrium Therapeutics (RNA) | two days later | +3.40% | final price |
| Atrium Therapeutics (RNA) | three days later | -2.45% | final price |
| Atrium Therapeutics (RNA) | three days earlier | +0.50% | final price |
| Atrium Therapeutics (RNA) | five days earlier | +2.14% | final price |
| SPY | that day | -0.42% | final price |
| SPY | the next day | +0.17% | final price |
| SPY | two days later | +0.11% | final price |
| SPY | three days later | +0.11% | final price |
| SPY | three days earlier | -0.28% | final price |
| SPY | five days earlier | -1.68% | final price |
| TLT | that day | +0.91% | final price |
| TLT | the next day | +1.04% | final price |
| TLT | two days later | +1.12% | final price |
| TLT | three days later | +1.54% | final price |
| TLT | three days earlier | -0.06% | final price |
| TLT | five days earlier | +0.73% | final price |
Who is named in “8-K - Atrium Therapeutics, Inc. (0002093101) (Filer)”
Companies tied to this story
- RNA Atrium Therapeutics
For “8-K - Atrium Therapeutics, Inc. (0002093101) (Filer),” Atrium Therapeutics (RNA) is linked, with no stored direction, high confidence. Reason on file: SEC 8-K filing -> direct issuer disclosure -> RNA
How “8-K - Atrium Therapeutics, Inc. (0002093101) (Filer)” reaches Atrium Therapeutics (RNA)
The 8 Oct 2026 story “8-K - Atrium Therapeutics, Inc. (0002093101) (Filer)” names Atrium Therapeutics (RNA) because of this story.
Atrium Therapeutics (RNA) is on the page because SEC 8-K filing -> direct issuer disclosure -> RNA
The price range for Atrium Therapeutics (RNA), and the dates in the story
RNA traded between 7.50 and 8.51 across 8 sessions. The latest close on file is 7.59.
A simple score for Atrium Therapeutics (RNA)
44 out of 100
“8-K - Atrium Therapeutics, Inc. (0002093101) (Filer)” scores 44 out of 100. The score uses 1 sources, a +5.55% difference versus the S&P 500 (SPY), and 1 linked companies.